Malignant Leptomeningeal Neoplasm
Associated Genetic Biomarkers
NCI Definition: A primary or metastatic malignant tumor involving the leptomeninges. 
There are 2 clinical trials for malignant leptomeningeal neoplasm, of which 2 are open and 0 are completed or closed. Of the trials that contain malignant leptomeningeal neoplasm as an inclusion criterion, 2 are phase 1 (2 open).
EGFR is the most frequent gene inclusion criterion for malignant leptomeningeal neoplasm clinical trials .
Iodine i 131 monoclonal antibody 8h9 and afatinib are the most common interventions in malignant leptomeningeal neoplasm clinical trials.
Significant Genes in Malignant Leptomeningeal Neoplasm
EGFR is an inclusion eligibility criterion in 1 clinical trial for malignant leptomeningeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and malignant leptomeningeal neoplasm as inclusion criteria, 1 is phase 1 (1 open) .
Afatinib is the most frequent therapy in malignant leptomeningeal neoplasm trials with EGFR mutations as inclusion criteria .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.